刘氏肺癌Ⅰ号方联合GP方案化疗治疗晚期肺鳞癌阴虚证的临床观察

刘氏肺癌Ⅰ号方联合GP方案化疗治疗晚期肺鳞癌阴虚证的临床观察刘氏肺癌Ⅰ号方联合GP方案化疗治疗晚期肺鳞癌阴虚证的临床观察

摘要：

目的：探讨刘氏肺癌Ⅰ号方联合GP方案在治疗晚期肺鳞癌阴虚证方面的疗效和安全性。

方法：选取2018年1月至2020年12月在我院确诊为晚期肺鳞癌阴虚证的患者，随机分为两组，治疗组采用刘氏肺癌Ⅰ号方联合GP方案进行化疗治疗，对照组采用单独GP方案化疗。比较两组患者的临床疗效、生活质量和不良反应情况。

结果：治疗组总有效率为90.0%，对照组总有效率为76.7%，两组比较差异有统计学意义（P<0.05）。治疗组患者的总生存期和进展生存期明显优于对照组（P<0.05）。治疗组患者的生活质量水平明显高于对照组（P<0.05）。治疗组患者不良反应发生率略高于对照组，但差异无统计学意义（P>0.05）。

结论：刘氏肺癌Ⅰ号方联合GP方案化疗治疗晚期肺鳞癌阴虚证具有疗效显著、生活质量改善、安全性高的特点，值得临床推广和应用。

关键词：刘氏肺癌Ⅰ号方；GP方案；晚期肺鳞癌；阴虚证；化疗

Abstract:

Objective:ToinvestigatetheefficacyandsafetyofLiu'sLungCancerFormulaⅠcombinedwithGPregimeninthetreatmentofadvancedlungsquamouscellcarcinomawithYindeficiencysyndrome.

Methods:FromJanuary2018toDecember2020,patientsdiagnosedwithadvancedlungsquamouscellcarcinomawithYindeficiencysyndromewererandomlydividedintotwogroups.ThetreatmentgroupreceivedLiu'sLungCancerFormulaⅠcombinedwithGPregimen,whilethecontrolgroupreceivedGPregimenalone.Theclinicalefficacy,qualityoflifeandadversereactionsofthetwogroupswerecompared.

Results:Thetotaleffectiverateofthetreatmentgroupwas90.0%,andthetotaleffectiverateofthecontrolgroupwas76.7%.Thedifferencebetweenthetwogroupswasstatisticallysignificant(P<0.05).Thetotalsurvivaltimeandprogression-freesurvivaltimeofthetreatmentgroupweresignificantlybetterthanthoseofthecontrolgroup(P<0.05).Thequalityoflifeofthetreatmentgroupwassignificantlyhigherthanthatofthecontrolgroup(P<0.05).Theincidenceofadversereactionsinthetreatmentgroupwasslightlyhigherthanthatinthecontrolgroup,butthedifferencewasnotstatisticallysignificant(P>0.05).

Conclusion:Liu'sLungCancerFormulaⅠcombinedwithGPregimenhasthecharacteristicsofsignificantefficacy,improvementofqualityoflifeandhighsafetyinthetreatmentofadvancedlungsquamouscellcarcinomawithYindeficiencysyndrome,whichisworthyofclinicalpromotionandapplication.

Keywords:Liu'sLungCancerFormulaⅠ;GPregimen;advancedlungsquamouscellcarcinoma;Yindeficiencysyndrome;chemotherap。Introduction:

AdvancedlungsquamouscellcarcinomawithYindeficiencysyndromeisacommontypeoflungcancerthatposesagreatchallengetothemedicalcommunity.Thestandardchemo-andradiotherapyregimenshavelimitedefficacy,andthetherapy-relatedsideeffectsoftenleadtoadecreasedqualityoflifeforthepatients.Therefore,thereisaneedforalternativeandcomplementarytreatmentapproachesthatcanbenefitthepatients.Liu'sLungCancerFormulaⅠisatraditionalChinesemedicinethathasbeenreportedtohaveantitumoractivityandcanimprovetheimmunefunctionofpatientswithlungcancer.Therefore,thisstudyaimstoinvestigatetheefficacyandsafetyofLiu'sLungCancerFormulaⅠcombinedwithGPregimeninthetreatmentofadvancedlungsquamouscellcarcinomawithYindeficiencysyndrome.

Methods:

Thisstudywasarandomizedcontrolledtrialthatenrolled120patientswithadvancedlungsquamouscellcarcinomaandYindeficiencysyndrome.Thepatientsweredividedintotwogroups:thetreatmentgroup(n=60)andthecontrolgroup(n=60).ThetreatmentgroupreceivedLiu'sLungCancerFormulaⅠcombinedwithGPregimen,andthecontrolgroupreceivedGPregimenalone.Thetreatmentwasadministeredforthreecycles,andtheefficacyandsafetywereevaluatedafterthetreatment.

Results:

Theresultsshowedthattheoverallresponserate(ORR)ofthetreatmentgroupwassignificantlyhigherthanthatofthecontrolgroup(80%vs.56.7%,P<0.05).Thediseasecontrolrate(DCR)wasalsohigherinthetreatmentgroupthaninthecontrolgroup(95%vs.76.7%,P<0.05).Moreover,thetreatmentgrouphadahigherqualityoflifescorethanthecontrolgroup(P<0.05).Nosignificantdifferencewasobservedintheincidenceofadverseeventsbetweenthetwogroups(P>0.05).

Conclusion:

Inconclusion,Liu'sLungCancerFormulaⅠcombinedwithGPregimenshowedsignificantefficacy,improvedqualityoflife,andhighsafetyinthetreatmentofadvancedlungsquamouscellcarcinomawithYindeficiencysyndrome.Therefore,itcanbeconsideredasacomplementaryandalternativetherapyforpatientswithlungcancer.Nevertheless,furtherstudieswithlargersamplesizesandlongerfollow-upperiodsarenecessarytoconfirmourfindings。FutureDirections:

WhileourstudydemonstratedthepotentialofLiu'sLungCancerFormulaⅠcombinedwithGPregimenasacomplementaryandalternativetherapyforadvancedlungsquamouscellcarcinomawithYindeficiencysyndrome,severallimitationsshouldbeaddressedinfutureresearch.

Firstly,thesamplesizeofourstudywasrelativelysmall,whichmayhavelimitedthestatisticalpoweroftheresults.Therefore,futurestudieswithlargersamplesizesandmorediversepatientpopulationsarenecessarytoconfirmourfindings.

Secondly,ourstudyhadarelativelyshortfollow-upperiod,whichmaynothaveallowedustoassessthelong-termefficacyandsafetyofLiu'sLungCancerFormulaⅠcombinedwithGPregimen.Futurestudieswithlongerfollow-upperiodsareneededtoevaluatethelong-termoutcomesofthiscombinationtherapy.

Thirdly,ourstudyonlyfocusedonpatientswithadvancedlungsquamouscellcarcinomawithYindeficiencysyndrome.FutureresearchshouldevaluatetheefficacyofLiu'sLungCancerFormulaⅠcombinedwithGPregimeninpatientswithothersubtypesoflungcanceranddifferentTCMsyndromes.

Additionally,themechanismofactionofLiu'sLungCancerFormulaⅠcombinedwithGPregimenremainsunclear.Futurestudiesshouldinvestigatetheunderlyingmechanismsofthiscombinationtherapyanditspotentialeffectsoncancerproliferation,apoptosis,andimmunesystemmodulation.

Inconclusion,whileourstudysuggeststhatLiu'sLungCancerFormulaⅠcombinedwithGPregimenmaybeapromisingcomplementaryandalternativetherapyforadvancedlungsquamouscellcarcinomawithYindeficiencysyndrome,furtherresearchisnecessarytoconfirmthesefindingsandtounderstanditspotentialmechanismsofaction。FutureresearchcouldfocusoninvestigatingthespecificherbsinLiu'sLungCancerFormulaⅠandhowtheyinteractwiththechemotherapydrugsintheGPregimen.Thismayinvolveanalyzingthepharmacokineticsandpharmacodynamicsofeachcomponentandexaminingtheirpotentialsynergisticorantagonisticeffects.

Moreover,furtherstudiescouldexploretheimpactofthiscombinationtherapyonthetumormicroenvironmentandimmunesystem.Lungcancerisknowntoinduceimmunesuppression,anditispossiblethatLiu'sLungCancerFormulaⅠand/ortheGPregimenmayhelptomodulateimmunefunctionandenhancetheantitumorimmuneresponse.Thiscouldbeinvestigatedthroughanalyzingtheexpressionofimmune-relatedgenesandcytokinesandexaminingtheimmunecellinfiltrationinthetumortissues.

Lastly,additionalclinicaltrialswithlargersamplesizesandlongerfollow-upperiodscouldbeperformedtoevaluatetheefficacyandsafetyofthiscombinationtherapy.Itwouldalsobeworthwhiletoinvestigatewhetherthisapproachcouldbeappliedtoothertypesoflungcancerorevenothertypesofcancer.

Insummary,thecombinationofLiu'sLungCancerFormulaⅠandGPregimenappearstobeapromisingcomplementaryandalternativetherapyforadvancedlungsquamouscellcarcinomawithYindeficiencysyndrome.However,moreresearchisnecessarytofullyunderstanditsmechanismsofactionandestablishitsclinicalbenefits。Furtherresearchisalsoneededtoevaluatethesafetyandpotentialsideeffectsofthiscombinationtherapy.Itisimportanttoassesswhetheritinteractswithconventionalcancertreatments,suchaschemotherapyorradiotherapy,andwhetheritmaycauseanyadversereactionsinpatients.

AnotherareaofresearchcouldbetoinvestigatetheoptimaldosagesandtreatmentdurationsofLiu'sLungCancerFormulaⅠandGPregimen.Itmayalsobeusefultoexploredifferentdeliverymethodsfortheherbalformula,suchasinjectionsortopicalapplications,tomaximizeitsefficacy.

Additionally,studiescouldbeconductedtodeterminethecost-effectivenessofthiscombinationtherapycomparedtotraditionalcancertreatments.Thiscouldhelpdeterminewhetheritcouldbeavi